Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 12/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.74 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dadle SCHEMBL11683986 | 0.94 | OPRD1 (0.80) | OPRD1OPRM1OPRK1 | |
| Dadle SCHEMBL11396067 | 0.94 | OPRD1 (0.80) | OPRD1OPRM1OPRK1 | |
| Dadle SCHEMBL16620196 | 0.94 | OPRD1 (0.80) | OPRD1OPRM1OPRK1 | |
| Dadle SCHEMBL11396064 | 0.94 | OPRD1 (0.80) | OPRD1OPRM1OPRK1 | |
| Dadle SCHEMBL11124725 | 0.94 | OPRD1 (0.80) | OPRD1OPRM1OPRK1 | |
| Dadle SCHEMBL28363457 | 0.94 | OPRD1 (0.80) | OPRD1OPRM1OPRK1 | |
| SCHEMBL30452341 | 0.92 | OPRD1 (0.66) | OPRD1OPRM1OPRK1 | |
| SCHEMBL11491134 | 0.91 | OPRD1 (0.78) | OPRD1OPRM1OPRK1 | |
| SCHEMBL9819593 | 0.90 | OPRD1 (0.71) | OPRD1OPRM1OPRK1 | |
| SCHEMBL31235887 | 0.89 | OPRD1 (0.64) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564579-B2 | Topical formulations of (1S)-1-phenyl-2-pyridin-2-ylethanamine | BIOHAVEN THERAPEUTICS LTD. (VG) | 2026-03-03 | — | — | US | disclosed |
| CN-120137162-A | Dynamic liquid crystal elastomer material and preparation method of actuator thereof | 四川大学 | 2025-06-13 | — | — | CN | disclosed |
| EP-4554959-A2 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | Pep2Tango Therapeutics Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-112823288-B | Method and system for determining the position of a plurality of transmission nodes | 仁爱解决方案公司 | 2024-08-02 | — | — | CN | disclosed |
| EP-4370537-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | Pep2Tango Therapeutics Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240059753-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2024015922-A2 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230190719-A1 | TOPICAL FORMULATIONS OF (1S)-1-PHENYL-2-PYRIDIN-2-YLETHANAMINE | BIOHAVEN THERAPEUTICS LTD (US) | 2023-06-22 | — | — | US | disclosed |
| EP-4168116-A1 | TOPICAL FORMULATIONS OF (1S)-1-PHENYL-2-PYRIDIN-2-YLETHANAMINE | Biohaven Therapeutics Ltd. (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-115836052-A | Topical formulations of (1S) -1-phenyl-2-pyridin-2-ylethylamine | 拜尔哈文制药股份有限公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4126888-A1 | COMPOUNDS USEFUL IN HIV THERAPY | VIIV Healthcare Company (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2023288313-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-11442138-B2 | Method and system for determining a position of a plurality of transmitting nodes | HUMANITAS SOLUTIONS INC (CA) | 2022-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | IAPP, GPR119, GIPR | OPRD1 653/4885OPRM1 402/4885OPRK1 253/4885 |
| US-20240059753-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | IAPP, GPR119, GIPR | OPRD1 653/4885OPRM1 402/4885OPRK1 253/4885 |
| US-12564579-B2 | Topical formulations of (1S)-1-phenyl-2-pyridin-2-ylethanamine | CERS2, CNR2, FAAH2 | OPRD1 696/4885OPRM1 507/4885OPRK1 1115/4885 |
| US-20230190719-A1 | TOPICAL FORMULATIONS OF (1S)-1-PHENYL-2-PYRIDIN-2-YLETHANAMINE | TRPV1, PNN, SLC18A2 | OPRD1 51/4885OPRM1 99/4885OPRK1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.